Statistics about Health, Pharma & Medtech in United States
Statistics
- Inhibikase Therapeutics revenue 2020-2023
- Innoviva net income 2019-2023
- Inozyme Pharma net income 2019-2023
- Inhibitor Therapeutics net income 2017-2021
- Sarepta Therapeutics revenue 2019-2023
- Inhibrx net income 2019-2021
- Immunome net income 2021-2023
- Scholar Rock Holding revenue 2018-2022
- Inmune Bio revenue 2018-2023
- Inmune Bio net income 2020-2022
- Immunitybio total equity 2019-2023
- Immunitybio total assets 2019-2023
- Sarepta Therapeutics net income 2019-2023
- Immunitybio net cash 2019-2023
- Scholar Rock Holding net income 2019-2023
- Savara net income 2019-2023
- Satsuma Pharmaceuticals, Inc. net income 2018-2022
- Senti Biosciences total equity 2020-2023
- Inhibrx revenue 2019-2023
- Scholar Rock Holding operating profit 2019-2023
- Inhibrx liabilities 2019-2023
- Inhibitor Therapeutics operating profit 2019-2023
- Immunogen, Inc. liabilities 2018-2022
- Geron revenue 2019-2023
- Indaptus Therapeutics, Inc. liabilities 2020-2023
- Immunovant, Inc. liabilities 2019-2023
- Geron net income 2019-2023
- Geron operating profit 2019-2023
- Inozyme Pharma operating profit 2019-2023
- Inhibikase Therapeutics liabilities 2020-2023
- Innoviva operating profit 2017-2021
- Innoviva revenue 2019-2023
- Scholar Rock Holding liabilities 2019-2023
- Inmune Bio operating profit 2019-2023
- Sarepta Therapeutics liabilities 2019-2023
- Immunogen, Inc. operating profit 2018-2022
- Immunome operating profit 2019-2023
- Inhibrx operating profit 2019-2023
- Indaptus Therapeutics, Inc. operating profit 2020-2023
- Inhibikase Therapeutics operating profit 2020-2023
- Sarepta Therapeutics operating profit 2019-2023
- Globestar Therapeutics Corp total assets 2018-2022
- Innoviva total assets 2019-2023
- Immunitybio operating profit 2019-2023
- Jaguar Health operating profit 2019-2023
- Shattuck Labs total equity 2019-2023
- Intra-Cellular Therapies liabilities 2019-2023
- Jaguar Health liabilities 2019-2023
- International Stem Cell liabilities 2019-2023
- Savara total equity 2019-2023
- Satsuma Pharmaceuticals, Inc. total equity 2018-2022
- Johnson & Johnson operating profit 2010-2014
- Glycomimetics total equity 2019-2023
- Glycomimetics total assets 2019-2023
- Innovation1 Biotech liabilities 2016-2023
- Glycomimetics liabilities 2019-2023
- Glycomimetics net cash 2019-2023
- Innovation1 Biotech operating profit 2019-2023
- Savara total assets 2019-2023
- Glycomimetics operating profit 2019-2023
- Galecto total equity 2019-2023
- International Stem Cell operating profit 2019-2023
- Intra-Cellular Therapies operating profit 2019-2023
- Galecto total assets 2019-2023
- Generex Biotechnology gross profit 2011-2020
- Generex Biotechnology revenue 2018-2019
- Galecto net cash 2019-2023
- Intra-Cellular Therapies net cash 2019-2023
- Intra-Cellular Therapies total assets 2019-2023
- Johnson & Johnson net cash 2019-2023
- Scilex Holding Company net cash 2020-2023
- Scilex Holding Company total equity 2020-2023
- Generex Biotechnology liabilities 2016-2020
- Generex Biotechnology total assets 2016-2020
- Scilex Holding Company liabilities 2020-2023
- Jaguar Health net cash 2019-2023
- Scilex Holding Company total assets 2020-2023
- Johnson & Johnson liabilities 2019-2023
- Scilex Holding Company revenue 2020-2023
- Innovation1 Biotech net cash 2019-2023
- International Stem Cell net cash 2019-2023
- Scilex Holding Company net income 2020-2023
- Generex Biotechnology operating profit 2016-2020
- Generex Biotechnology total equity 2016-2020
- Scilex Holding Company operating profit 2020-2023
- Generex Biotechnology net cash 2016-2020
- Generex Biotechnology net income 2011-2015
- Glycomimetics revenue 2016-2023
- Johnson & Johnson gross profit 2019-2023
- Sarepta Therapeutics total equity 2019-2023
- Shattuck Labs revenue 2019-2023
- Inhibitor Therapeutics total equity 2019-2023
- Innoviva total equity 2018-2022
- Satsuma Pharmaceuticals, Inc. operating profit 2018-2022
- Inozyme Pharma total equity 2019-2023
- Global Wholehealth Partners Corp total assets 2014-2022
- Global Wholehealth Partners Corp total equity 2018-2022
- Global Wholehealth Partners Corp gross profit 2020-2022
- Inmune Bio total equity 2019-2023
- Inhibrx total equity 2019-2023